key: cord-0987604-30x2ej4p
authors: Tong, Ming; Jiang, Yu; Xia, Da; Xiong, Ying; Zheng, Qing; Chen, Fang; Zou, Lianhong; Xiao, Wen; Zhu, Yimin
title: Elevated Serum Endothelial Cell Adhesion Molecules Expression in COVID-19 Patients
date: 2020-06-25
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa349
sha: ca95980d867c8a3922d604154f1fc07a574a1ec8
doc_id: 987604
cord_uid: 30x2ej4p

In a retrospective study of 39 COVID-19 patients and 32 control participants in China, we collected clinical data and examined the expression of endothelial cell adhesion molecules by enzyme-linked immunosorbent assays. Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) elevated in mild patients, dramatically in severe cases, while decreased in the convalescence phase. In conclusion, the increased expression of endothelial cell adhesion molecules is related to COVID-19 and disease severity and may contribute to coagulation dysfunction.

In December 2019, a severe public health event mainly manifested with fever and respiratory tract symptoms broke out in Wuhan, China, and quickly spread throughout the country and the world [1] , which was then named "coronavirus disease 2019(COVID-19)" by the World Health Organization.

As of May 1, 2020, more than three million cases have been confirmed, while more than two hundred thousand patients have died, and the number is overgrowing.

COVID-19 causes a systemic inflammatory response, involving dysregulation and misexpression of many inflammatory cytokines [1] . The recruitment and activation of inflammatory cells depend on the expression of many classes of inflammatory mediators, such as cytokines (interleukin(IL)-1, IL-6, and IL-18), chemokines (fractalkine, FKN), and adhesion molecules (intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1(VCAM-1)) [2] . Pathological evidence of venous thromboembolism, direct viral infection of the endothelial cells and diffuse endothelial inflammations have been reported in recent studies [2, 3] . Therefore, it is significant to investigate the expression of endothelial cell adhesion molecules in COVID-19.

Here, we collected clinical data and blood samples from confirmed COVID-19 patients in the Fourth People's Hospital of Yiyang in Hunan, China, and performed Enzyme-linked immunosorbent assays (ELISAs) to study the expression of inflammatory mediators and endothelial cell adhesion molecules in COVID-19 patients.

A c c e p t e d M a n u s c r i p t 4

A retrospective study was conducted. From February 1 to March 10, 2020, thirty-nine COVID-19 patients were recruited at the Infectious Disease Ward in the Fourth People's Hospital of Yiyang in Hunan, China, and thirty-two uninfected participants were recruited from the physical examination center of Hunan Provincial People's Hospital. All patients were tested positive with SARS-CoV-2 and hospitalized. Nine patients were diagnosed with severe pneumonia, while thirty had mild disease.

Mild pneumonia was defined as positivity in qRT-PCR tests, with typical chest tomography imaging features of viral pneumonia [4] , while severe pneumonia was defined as mild pneumonia plus one of the following criteria: 1) Respiratory distress with a respiratory rate ≥30 times per minute;

2) Oxygen saturation ≤93% at rest;

3) Oxygenation index ≤ 300mmHg (1mmHg = 0.133kPa); 4) Respiratory failure requiring ventilation; 5) Refractory shock; 6) Admission to the ICU for other organ failure.

All patients were given interferon α-2b (5 million units twice daily, atomization inhalation) and lopinavir plus ritonavir (500 mg twice daily, orally) as antiviral therapy. All severe patients received preventive anticoagulant treatment with low-molecular-weight heparin(LMWH) 5000 IU/day by subcutaneous injection for seven days. No patients died during the observation period.

The criteria for discharge were: 1) Absence of fever for at least three days;

2) Significant improvement in both lungs on chest CT; Clinical data were measured at enrolment. The ethics committee of the local hospital approved the study. All study participants provided written informed consent.

Blood samples were collected at admission from each patient in a fasting state and repeated during the convalescence period for severe cases. Serum lipids, glucose, C-reaction protein(CRP), and D-dimer were determined by conventional laboratory methods. Blood samples of control subjects were also collected and tested. The obtained blood samples were placed in tubes containing EDTA and immediately centrifuged at 1500×g and stored at −80°C.

Quantitative determination of IL-18, tumor necrosis factor-alpha(TNF-α), interferon-gamma (IFN-γ), FKN, VCAM-1, ICAM-1, and vascular adhesion protein-1 (VAP-1) was performed using commercially available ELISA kits from BOSTER (BOSTER, Wuhan, China).

Categorical variables were reported as the counts and percentages, and significance was detected by chi-square or Fisher's exact test. The continuous variables were compared using independent group ttests and described using mean and standard deviation if normal distributed, or compared using the Mann-Whitney U test and Kruskal-Wallis H test and described using median and interquartile range (IQR) value if not. Paired comparisons of the severe groups were analyzed with the Nemenyi test. 

In this retrospective study, no patients were directly involved in the study design, question proposal, or the outcome measurements. No patients were asked for input concerning interpretation or recording of the results.

Demographic information is shown in Table 1 . Briefly, twenty patients were males, nineteen patients were females, sixteen controls were males, and sixteen were females, and the median ages in the control, mild, and severe groups were 52, 49, and 54 years, respectively. Nine patients were severe cases, while thirty cases were mild. No significant differences were found between mild patients and Endothelial activation is related to severe COVID-19, and antiphospholipid antibodies, VWF, and FVIII may play a role in coagulopathy [5] . Endothelial cells express ACE2, the receptor for SARS-CoV-2 [6] , and the interaction of SARS-CoV-2 and ACE2 possibly mediates endothelial activation.

Endothelial cells are an essential component of the coagulation system and their integrity and functionality are critical to maintaining haemostasis, whereas endothelial cell activation or injury may result in platelet activation, thrombosis, and inflammation [7] . Dysfunctional endothelial cells activated by pro-inflammatory cytokines may contribute to the pathogenesis of thrombosis by altering the expression of pro-and antithrombotic factors [8, 9] .

In the cohort, although apparent thrombosis formation was excluded by Doppler ultrasound in deep veins in the lower extremities and repeated chest CT scans, we found an interesting phenomenon in severe patients: serum D-dimer levels were elevated during the acute phase and decreased significantly during the convalescence phase. As an indirect marker of coagulation activation, elevated D-dimer was reported in several studies and confirmed to correlate with an increased likelihood of death in COVID-19 patients [10] . We suppose that the relationship between pre-A c c e p t e d M a n u s c r i p t 9 thrombosis levels of D-dimer and thrombotic disease is likely partly attributable to subclinical clot formation.

Severe COVID-19 is commonly complicated with coagulopathy, while disseminated intravascular coagulation (DIC) may contribute to most deaths [11] . Anticoagulant treatment may decrease mortality with coagulopathy [12] . For severe patients, serum FKN, ICAM-1, VCAM-1, and D-dimer levels declined significantly after anti-viral and anticoagulant treatment. In addition to stimulating the immune system to suppress viral replication and clear pathogens, interferon-α also inhibits the inflammatory immune response that leads to histological damage [13] . Hence, we speculate that the dynamic changes in these molecules resulted from the alleviation of endothelial cell injuries, the antiinflammatory effect of medications, or recovery from COVID-19.

Limitations should be noted when interpreting the results of this study. First, the number of severe patients was too small, which may lead to statistical deviation. Second, due to tissue sample inaccessibility, the expression of endothelial activation molecules was not measured in tissues. Third, since we did not measure the direct biomarkers in the coagulation system, the specific disturbed pathways and mechanisms are still unknown. Fourth, due to the anti-inflammatory effect of interferon-α, the relationship between the anticoagulant effect of LMWH and the decreased expression of endothelial cell adhesion molecules in COVID-19 is still uncertain, which requires further study.

Based on the study results, increased expression of endothelial cell adhesion molecules is related to COVID-19 and disease severity and may contribute to coagulation dysfunction.

A c c e p t e d M a n u s c r i p t 10 M a n u s c r i p t A c c e p t e d M a n u s c r i p t 13 Figure 1 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Endothelial cell infection and endotheliitis in COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Severe COVID-19 infection associated with endothelial activation

ACE2: from vasopeptidase to SARS virus receptor

Vascular Endothelial Cell Biology: An Update

Interleukin-1 mediates ischaemic brain injury via distinct actions on endothelial cells and cholinergic neurons

Asiaticoside Inhibits TNF-α-Induced Endothelial Hyperpermeability of Human Aortic Endothelial Cells

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The Dual Nature of Type I and Type II Interferons

On behalf of the authors, we sincerely thank clinicians in Forth People's Hospital of Yiyang, Hunan, China.

The present study was supported by the Key Research and Development Program of Hunan Province (Grant 2020SK3011).

This study was approved by the Medical Ethics Review Board of Hunan Provincial People's Hospital (No. 2020-10).

The authors declare that they have no competing interests.A c c e p t e d M a n u s c r i p t